A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

Cited by (999)

Items 101–200 of 999

1. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression
   Ruiping Wang, Shumei Song, Jiang‐Jiang Qin, Katsuhiro Yoshimura, Fuduan Peng, Yanshuo Chu, Yuan Li, Yibo Fan, Jiankang Jin, Minghao Dang et al. · 2023 · Cancer Cell
2. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation
   Jaikumar Duraiswamy, Riccardo Turrini, Aspram Minasyan, David Barras, Isaac Crespo, Alizée J Grimm, Julia Casado, Raphaël Genolet, Fabrizio Benedetti, Alexandre M. Wicky et al. · 2021 · Cancer Cell
3. Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity
   Chao Yang, Jingsi Jin, Yuanqin Yang, Hongxiang Sun, Lingling Wu, Mingyi Shen, Xiaochuan Hong, Wenwen Li, Lu Lu, Dongqing Cao et al. · 2022 · Immunity
4. The role of CDK6 in cancer
   Sofie Nebenfuehr, Karoline Kollmann, Veronika Sexl · 2020 · International Journal of Cancer
5. Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy
   Erik S. Knudsen, Steven C. Pruitt, Pamela A. Hershberger, Agnieszka Katarzyna Witkiewicz, David W. Goodrich · 2019 · Trends in cancer
6. Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma
   Limeta, Angelo, Ji, Boyang, Levin, Max, Gatto, Francesco, Nielsen, Jens · 2020 · JCI Insight
7. Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis
   Roarke A. Kamber, Yoko Nishiga, Bhek Morton, Allison M. Banuelos, Amira A. Barkal, Felipe Vences‐Catalán, Mingxin Gu, Daniel Fernández, José Antonio Seoane, David Yao et al. · 2021 · Nature
8. Mime: A flexible machine-learning framework to construct and visualize models for clinical characteristics prediction and feature selection
   Hongwei Liu, Wei Zhang, Yihao Zhang, Abraham Ayodeji Adegboro, Deborah Oluwatosin Fasoranti, Luohuan Dai, Zhouyang Pan, Hongyi Liu, Yi Xiong, Wang Li et al. · 2024 · Computational and Structural Biotechnology Journal
9. Germline genetic contribution to the immune landscape of cancer
   Rosalyn W. Sayaman, Mohamad Saad, Vésteinn Thórsson, Donglei Hu, Wouter Hendrickx, Jessica P Roelands, Eduard Porta‐Pardo, Younes Mokrab, Farshad Farshidfar, Tomas Kirchhoff et al. · 2021 · Immunity
10. B-cell-specific checkpoint molecules that regulate anti-tumour immunity
    Lloyd Bod, Yoon-Chul Kye, Jingwen Shi, Elena Torlai Triglia, Alexandra Schnell, Johannes Fessler, Stephen M. Ostrowski, Max von Franque, Juhi R. Kuchroo, Rocky Barilla et al. · 2023 · Nature
11. Current and Future Clinical Applications of ctDNA in Immuno-Oncology
    Julia-Christina Stadler, Yassine Belloum, Benjamin Deitert, Mark Sementsov, Isabel Heidrich, Christoffer Gebhardt, Laura Keller, Klaus Pantel · 2021 · Cancer Research
12. SciBet as a portable and fast single cell type identifier
    Chenwei Li, Baolin Liu, Boxi Kang, Zedao Liu, Yedan Liu, Changya Chen, Xianwen Ren, Zemin Zhang · 2020 · Nature Communications
13. Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment
    Kerri‐Ann Norton, Chang Gong, Samira Jamalian, Aleksander S. Popel · 2019 · Processes
14. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
    Amy L. Shergold, Rhona Millar, Robert J. B. Nibbs · 2019 · Pharmacological Research
15. Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action
    McFarland, James M., Paolella, Brenton R., Warren, Allison, Geiger-Schuller, Kathryn, Shibue, Tsukasa, Rothberg, Michael, Kuksenko, Olena, Colgan, William N., Jones, Andrew, Chambers, Emily et al. · 2020 · Nature Communications
16. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
    Zhenyi Niu, Runsen Jin, Yan Zhang, Hecheng Li · 2022 · Signal Transduction and Targeted Therapy
17. Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)
    Nune Markosyan, Jinyang Li, Yu Huining Sun, Lee P. Richman, Jeffrey H. Lin, Fangxue Yan, Liz Quinones, Yogev Sela, Taiji Yamazoe, Naomi Gordon et al. · 2019 · Journal of Clinical Investigation
18. Immunomodulation by anticancer cell cycle inhibitors
    Petroni, Giulia, Formenti, Silvia C., Chen-Kiang, Selina, Galluzzi, Lorenzo · 2020 · Nature Reviews Immunology
19. Self-Delivery Photo-Immune Stimulators for Photodynamic Sensitized Tumor Immunotherapy
    Linping Zhao, Rongrong Zheng, Jiaqi Huang, Xia‐Yun Chen, Fu‐An Deng, Yibin Liu, Chu‐Yu Huang, Xiyong Yu, Hong Bo Cheng, Shiying Li · 2020 · ACS Nano
20. The immune landscape and response to immune checkpoint blockade therapy in lymphoma
    Justin Paul Kline, James K. Godfrey, Stephen Maxted Ansell · 2019 · Blood
21. Integrated single-cell analysis of multicellular immune dynamics during hyperacute HIV-1 infection
    Samuel W. Kazer, Toby P. Aicher, Daniel Muema, Shaina L. Carroll, José Ordovás-Montañés, Vincent N. Miao, Ang Andy Tu, Carly G.K. Ziegler, Sarah K. Nyquist, Emily Beth Wong et al. · 2020 · Nature Medicine
22. Overcoming the senescence‐associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer
    Cecilia R. Chambers, Shona Ritchie, Brooke Pereira, Paul Timpson · 2021 · Molecular Oncology
23. Metabolism drives macrophage heterogeneity in the tumor microenvironment
    Shasha Li, Jiali Yu, Amanda K. Huber, Ilona Kryczek, Zhuwen Wang, Long Jiang, Xiong Li, Wan Du, Gaopeng Li, Shuang Wei et al. · 2022 · Cell Reports
24. Molecular determinants of response to PD-L1 blockade across tumor types
    Romain Banchereau, Ning Leng, Oliver A. Zill, Ethan S. Sokol, Gengbo Liu, Dean Pavlick, Sophia Lisette Maund, Li-Fen Liu, Edward Ernest Kadel, Nicole E. Baldwin et al. · 2021 · Nature Communications
25. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
    Giulia Petroni, Aitziber Buqué, Lisa M. Coussens, Lorenzo Galluzzi · 2022 · Nature Reviews Drug Discovery
26. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy
    Qinghua Wang, Meiling Li, Meng Yang, Yichen Yang, Fengju Song, Wei Zhang, Xiangchun Li, Kexin Chen · 2020 · Aging
27. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state
    Daniela Cerezo‐Wallis, Marta Contreras-Alcalde, Kevin Troulé, Xavier Catena, Cynthia Mucientes, Tonantzin G. Calvo, Estela Cañón, Cristina Tejedo, Paula Comune Pennacchi, Sabrina A. Hogan et al. · 2020 · Nature Medicine
28. Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment
    Quentin Haas, Kayluz Frias Boligan, Camilla Jandus, Christoph Schneider, Cédric Simillion, Michal A. Stanczak, Monika Haubitz, S. Morteza Seyed Jafari, Alfred Zippelius, Gabriela Maria Baerlocher et al. · 2019 · Cancer Immunology Research
29. Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer
    Hui Yang, Jinghui Cheng, Hao Zhuang, Hongchuang Xu, Yinuo Wang, Tingting Zhang, Yinmo Yang, Hong-Gang Qian, Yinying Lu, Feng Han et al. · 2024 · Cancer Cell
30. PAK4 inhibition improves PD-1 blockade immunotherapy
    Gabriel Abril-Rodríguez, Davis Yuri Torrejon, Wei Liu, Jesse Meir Zaretsky, Theodore Scott Nowicki, Jennifer Tsoi, Cristina Puig-Saus, Ignacio Baselga-Carretero, Egmidio Medina, Michael J. Quist et al. · 2019 · Nature Cancer
31. Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation
    Mercedes Segovia, Sofía Russo, Mathías Jeldres, Yamil Damian Mahmoud, Valentina Perez, Maite Duhalde Vega, Pierre Charnet, Matthieu Rousset, Sabina Victoria, Florencia Veigas et al. · 2019 · Cancer Cell
32. Tim-3: A co-receptor with diverse roles in T cell exhaustion and tolerance
    Ruihan Tang, Manu Rangachari, Vijay Kumar Kuchroo · 2019 · Seminars in Immunology
33. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia
    Audrey Lasry, Bettina Nadorp, Maarten W.J. Fornerod, Deedra Nicolet, Huiyun Wu, Christopher James Walker, Zhengxi Sun, Matthew T. Witkowski, Anastasia N. Tikhonova, María Guillamot et al. · 2022 · Nature Cancer
34. Reconstruction of cell spatial organization from single-cell RNA sequencing data based on ligand-receptor mediated self-assembly
    Xianwen Ren, Guojie Zhong, Qiming Zhang, Lei Zhang, Yujie Sun, Zemin Zhang · 2020 · Cell Research
35. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
    Su Yin Lim, Elena Shklovskaya, Jenny Lee, Bernadette Pedersen, Ashleigh Stewart, Zizhen Ming, Mal Irvine, Brindha Shivalingam, Robyn P.M. Saw, Alexander Maxwell Menzies et al. · 2023 · Nature Communications
36. VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity
    Mohamed A. ElTanbouly, Walburga Croteau, Randolph J. Noelle, Janet Louise Lines · 2019 · Seminars in Immunology
37. Senescence as a therapeutically relevant response to CDK4/6 inhibitors
    Wagner, Verena, Gil, Jesús · 2020 · Oncogene
38. Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
    April C. S. Watt, Shom Goel · 2022 · Breast Cancer Research
39. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response
    Michelle von Locquenghien, Catalina Rozalén, Toni Celià-Terrassa · 2021 · Journal of Clinical Investigation
40. B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?
    Martin Lauss, Marco Donia, Inge Marie Svane, Goran B Jönsson · 2021 · Clinical Cancer Research
41. Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING
    Marine Bruand, David Barras, Marco Mina, Eleonora Ghisoni, Matteo Morotti, Evripidis Lanitis, Noémie Fahr, Mathieu Desbuisson, Alizée J Grimm, Hualing Zhang et al. · 2021 · Cell Reports
42. Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion
    Andrew J. Freeman, Stephin J. Vervoort, Kelly M. Ramsbottom, Madison J. Kelly, Jessica Michie, Lizzy Pijpers, Ricky W. Johnstone, Conor J. Kearney, Jane Oliaro · 2019 · Cell Reports
43. CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade
    Guangchuan Wang, Ryan Dz-Wei Chow, Lvyun Zhu, Zhigang Bai, Lupeng Ye, Feifei Zhang, Paul A. Renauer, Matthew B. Dong, Xiaoyun Dai, Xiaoya Zhang et al. · 2020 · Cancer Discovery
44. Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer
    Yuanyuan Zhang, Hongyan Chen, Hongnan Mo, Ning Zhao, Xiaoying Sun, Baolin Liu, Ranran Gao, Binghe Xu, Zemin Zhang, Zhihua Liu et al. · 2025 · Cancer Cell
45. A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
    Michael John Dickinson, Pere Barba, Ulrich Jaeger, Nirav Niranjan Shah, Didier Blaise, Javier Briones, Leyla Osman Shune, Nicolas Boissel, Attilio Bondanza, Luisa Mariconti et al. · 2023 · Cancer Discovery
46. Interpretable systems biomarkers predict response to immune-checkpoint inhibitors
    Óscar Lapuente-Santana, Maisa N.G. van Genderen, P.A.J. Hilbers, Francesca Finotello, Federica Eduati · 2021 · Patterns
47. Senescence and the tumor-immune landscape: Implications for cancer immunotherapy
    Loretah Chibaya, Jarin T. Snyder, Marcus A. Ruscetti · 2022 · Seminars in Cancer Biology
48. Human melanocyte development and melanoma dedifferentiation at single-cell resolution
    R.L. Belote, Daniel Le, Ashley Maynard, Ursula E. Lang, Adriane Watkins Sinclair, Brian K. Lohman, Vicente Planells-Palop, Laurence S. Baskin, Aaron D. Tward, Spyros Darmanis et al. · 2021 · Nature Cell Biology
49. Estimation of cell lineages in tumors from spatial transcriptomics data
    Beibei Ru, Jinlin Huang, Yu Zhang, Kenneth Aldape, Peng Jiang · 2023 · Nature Communications
50. Evolution of delayed resistance to immunotherapy in a melanoma responder
    David Liu, Jia‐Ren Lin, Emily J. Robitschek, Gyulnara G. Kasumova, Alex Heyde, Alvin Shi, Adam Kraya, Gao Zhang, Tabea O. C. Moll, Dennie Tompers Frederick et al. · 2021 · Nature Medicine
51. CDK4/6 inhibitors induce replication stress to cause long‐term cell cycle withdrawal
    Lisa Crozier, Reece Foy, Brandon L. Mouery, Robert H. Whitaker, Andrea Corno, Christos Spanos, Tony Ly, Jeanette Gowen Cook, Adrian Thomas Saurin · 2022 · The EMBO Journal
52. Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging
    Ziming Du, Jia‐Ren Lin, Rumana Rashid, Zoltan Maliga, Shu Wang, Jon Christopher Aster, Benjamin Izar, Peter Karl Sorger, Sandro Santagata · 2019 · Nature Protocols
53. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
    Wenjing Qian, Mingfang Zhao, Ruoyu Wang, Heming Li · 2021 · Journal of Hematology & Oncology
54. Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy
    Hellmann, Matthew D., Jänne, Pasi A., Opyrchal, Mateusz, Hafez, Navid, Raez, Luis E., Gabrilovich, Dmitry I., Wang, Fang, Trepel, Jane B., Lee, Min-Jung, Yuno, Akira et al. · 2021 · Clinical Cancer Research
55. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
    Lucille Stuani, Marie Sabatier, Feng Wang, Nathalie Poupin, Claudie Bosc, Estelle Saland, Florence Anne Castelli, Lara Gales, Camille Montersino, Emeline Boët et al. · 2021 · The Journal of Experimental Medicine
56. Targeting DNA repair pathway in cancer: Mechanisms and clinical application
    Manni Wang, Siyuan Chen, Danyi Ao · 2021 · MedComm
57. Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment
    John David Klement, Priscilla S. Redd, Chunwan Lu, Alyssa D. Merting, Dakota B. Poschel, Dafeng Yang, Natasha M. Savage, Gang Zhou, David H. Munn, Padraic G. Fallon et al. · 2023 · Cancer Cell
58. Cancer-associated fibroblast subtypes modulate the tumor-immune microenvironment and are associated with skin cancer malignancy
    Agnes Forsthuber, Bertram Aschenbrenner, Ana Korosec, Tina Jacob, Karl Annusver, Natalia Krajic, Daria Kholodniuk, Sophie Frech, Shaohua Zhu, Kim Purkhauser et al. · 2024 · Nature Communications
59. Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq data
    Coral Fustero Torre, María José Jiménez‐Santos, Santiago García‐Martín, Carlos Carretero-Puche, Luis García-Jimeno, Vadym Ivanchuk, Tomás Di Domenico, Gonzalo Goméz-López, Fátima Al‐Shahrour · 2021 · Genome Medicine
60. Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy.
    Weixin Chen, J. Teo, Siu-Wah Yau, M. Wong, Chun-Nam Lok, C. Che, Asif Javed, Yuan-Hua Huang, Stephanie Ma, Guang-Sheng Ling · 2022 · Cell Reports
61. Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
    Livnat Jerby‐Arnon, Cyril Neftel, Marni E. Shore, Hannah R. Weisman, Nathan D. Mathewson, Matthew J. McBride, Brian J. Haas, Benjamin Izar, Angela Volorio, Gaylor Boulay et al. · 2021 · Nature Medicine
62. EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance
    Loretah Chibaya, Katherine C. Murphy, Kelly D. DeMarco, Sneha Gopalan, Haibo Liu, Chaitanya Naimesh Parikh, Yvette Lopez-Diaz, Melissa Faulkner, Junhui Li, John P. Morris et al. · 2023 · Nature Cancer
63. Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives
    Sawsan Sudqi Said, Wisam Nabeel Ibrahim · 2023 · Pharmaceutics
64. TIGER: A Web Portal of Tumor Immunotherapy Gene Expression Resource
    Zhihang Chen, Ziwei Luo, Di Zhang, Huiqin Li, Xuefei Liu, Kaiyu Zhu, Hongwan Zhang, Zongping Wang, Penghui Zhou, Jian Min Ren et al. · 2022 · Genomics Proteomics & Bioinformatics
65. Cutaneous melanoma
    Alpaslan Tasdogan, Ryan Joseph Sullivan, Alexander Katalinic, Célèste Lebbé, Dagmar Whitaker, Susana Puig, Lonneke Veronique van de Poll-Franse, Daniela Massi, Dirk Schadendorf · 2025 · Nature Reviews Disease Primers
66. Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy
    Eva Pérez‐Guijarro, Howard Hua Yang, Romina Elizabeth Araya, Rajaâ El Meskini, Helen T. Michael, Suman Kumar Vodnala, Kerrie L. Marie, Cari Smith, Sung Chin, Khiem Chi Lam et al. · 2020 · Nature Medicine
67. From bench to bedside: Single-cell analysis for cancer immunotherapy
    Emily F. Davis-Marcisak, Atul M. Deshpande, Genevieve Stein-O’Brien, Won Jin Ho, Daniel A. Laheru, Elizabeth M. Jaffee, Elana Judith Fertig, Luciane Tsukamoto Kagohara · 2021 · Cancer Cell
68. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy
    Judith Wienke, Lindy L. Visser, Waleed M. Kholosy, Kaylee M. Keller, Marta Barisa, Evon Poon, Sophie Munnings-Tomes, Courtney Himsworth, Elizabeth A. Calton, Ana Isabel Enríquez Rodríguez et al. · 2024 · Cancer Cell
69. Recent advances in the clinical development of immune checkpoint blockade therapy
    Atefeh Ghahremanloo, Arash Soltani, Seyed Mohamad Sadegh Modaresi, Seyed Isaac Hashemy · 2019 · Cellular Oncology
70. Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy
    Simon Eschweiler, James D. Clarke, Ciro Ramírez-Suástegui, Bharat Panwar, Ariel Madrigal, Serena Chee, Ioannis Karydis, Edwin B.C. Woo, Aiman Alzetani, Somaia Elbauomy Elsheikh et al. · 2021 · Nature Immunology
71. Single-cell transcriptomic analysis highlights origin and pathological process of human endometrioid endometrial carcinoma
    Xiaojun Ren, Jianqing Liang, Yiming Zhang, Ning Jiang, Yuhui Xu, Mengdi Qiu, Yiqin Wang, Bing Tian Zhao, Xiaojun Chen · 2022 · Nature Communications
72. Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas
    Marina T. Broz, Emily Y. Ko, Kristin Ishaya, Jin-Fen Xiao, Marco Claudio De Simone, Xen Ping Hoi, Roberta Piras, Basia Gala, Fernando Henrique Galvão Tessaro, Anja Karlstaedt et al. · 2024 · Nature Communications
73. Combinatorial therapy in tumor microenvironment: Where do we stand?
    Smita Kumari, Dia Advani, Sudhanshu Sharma, Rashmi K. Ambasta, Pravir Kumar · 2021 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
74. Turning tumors from cold to inflamed to improve immunotherapy response
    Camille Lea Gerard, Julie Delyon, Alexandre M. Wicky, Krisztián Homicskó, Michel A. Cuendet, Olivier Alain Michielin · 2021 · Cancer Treatment Reviews
75. Inference of Gene Regulatory Network from Single-Cell Transcriptomic Data Using pySCENIC
    Nilesh Kumar, Bharat Mishra, Mohammad Athar, Shahid M. Mukhtar · 2021 · Methods in molecular biology
76. Large Scale Foundation Model on Single-cell Transcriptomics
    Hao, Minsheng, Gong, Jing, Zeng, Xin, Liu, Chiming, Guo, Yucheng, Cheng, Xingyi, Wang, Taifeng, Ma, Jianzhu, Song, Le, Zhang, Xuegong · 2023
77. DIALOGUE maps multicellular programs in tissue from single-cell or spatial transcriptomics data
    Livnat Jerby‐Arnon, Aviv Regev · 2022 · Nature Biotechnology
78. Immunoediting instructs tumor metabolic reprogramming to support immune evasion
    Chin‐Hsien Tsai, Yu‐Ming Chuang, Xiaoyun Li, Yi-Ru Yu, Sheue‐Fen Tzeng, Shao Thing Teoh, Katherine E. Lindblad, Mario Di Matteo, Wan-Chen Cheng, Pei‐Chun Hsueh et al. · 2023 · Cell Metabolism
79. Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities
    Mona Meng Wang, Sarah E. Coupland, Tero A. Aittokallio, Carlos R. Figueiredo · 2023 · British Journal of Cancer
80. Directing Traffic: How to Effectively Drive T Cells into Tumors
    Annabelle J. Anandappa, Catherine J. Wu, Patrick Alexander Ott · 2020 · Cancer Discovery
81. Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma
    Yan Kong, Canqiang Xu, Chuanliang Cui, Wenxian Yang, Shuang Yang, Zhihong Chi, Xinan Sheng, Lu Si, Yihong Xie, Rongshan Yu et al. · 2021 · npj Genomic Medicine
82. Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets
    Zhangfeng Zhong, Chi Teng Vong, Feiyu Chen, Horyue Tan, Cheng Zhang, Ning Wang, Liao Cui, Yitao Wang, Yibin Feng · 2022 · Medicinal Research Reviews
83. Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy
    Huan Song, Lin Chen, Xuanxuan Pan, Yuru Shen, Maolin Ye, Guohong Wang, Can Cui, Qi Zhou, Yujen Tseng, Zheng Gong et al. · 2025 · Cancer Cell
84. 3D models in the new era of immune oncology: focus on T cells, CAF and ECM
    Francesca Di Modugno, Cristina Colosi, Paola Trono, Giuseppe Antonacci, Giancarlo Ruocco, Paola Nisticò · 2019 · Journal of Experimental & Clinical Cancer Research
85. Biology of Melanoma
    Stephen M. Ostrowski, David E. Fisher · 2020 · Hematology/Oncology Clinics of North America
86. The aged tumor microenvironment limits T cell control of cancer
    Chang-Yu Chen, Sneha Jaiswal, Daniela Martínez, Cansu Yerinde, Keely Y. Ji, Velita Miranda, Megan E. Fung, Sarah A. Weiss, Maria Zschummel, Kazuhiro Taguchi et al. · 2024 · Nature Immunology
87. Using a pan-cancer atlas to investigate tumour associated macrophages as regulators of immunotherapy response
    Alexander Coulton, Jun Murai, Danwen Qian, Krupa Thakkar, Claire E. Lewis, Kevin Litchfield · 2024 · Nature Communications
88. Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients
    Yu Feng, Wenjuan Ma, Yupeng Zang, Yanying Guo, Young Li, Yixuan Zhang, Xuan Dong, Yi Liu, Xiaojuan Zhan, Zhizhong Pan et al. · 2024 · Nature Communications
89. The Immune Microenvironment and Cancer Metastasis
    Asmaa El-Kenawi, Kay Hänggi, Brian Ruffell · 2019 · Cold Spring Harbor Perspectives in Medicine
90. The Stress-Like Cancer Cell State Is a Consistent Component of Tumorigenesis
    Maayan Baron, Mohita M. Tagore, Miranda V. Hunter, Isabella S. Kim, Reuben M. Moncada, Yun Yan, Nathaniel R. Campbell, Richard Mark White, Itai Yanai · 2020 · Cell Systems
91. Gene regulatory network reconstruction: harnessing the power of single-cell multi-omic data
    Daniel J. Kim, Andy Tran, Hani Jieun Kim, Yingxin Lin, Jean Yee Hwa Yang, Pengyi Yang · 2023 · npj Systems Biology and Applications
92. Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance
    Heng Lin, Kole Tison, Yuheng Du, Paul D. Kirchhoff, Chan Kim, Weichao Wang, Hannah Yang, Michael Reginald Pitter, Jiali Yu, Peng Liao et al. · 2024 · Cancer Cell
93. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation
    Mara A. Bonelli, Silvia La Monica, Claudia Fumarola, Roberta R Alfieri · 2019 · Biochemical Pharmacology
94. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy
    Jiannong Li, Inna Smalley, Zhihua Chen, Jheng-Yu Wu, Manali S. Phadke, Jamie K. Teer, Thanh Nguyen, Florian A. Karreth, John M. Koomen, Amod A. Sarnaik et al. · 2022 · Clinical Cancer Research
95. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment
    Markus Haake, Beatrice Haack, Tina Schäfer, Patrick N. Harter, Greta Mattavelli, Patrick Eiring, Neha Vashist, Florian Wedekink, Sabrina Genßler, Birgitt Fischer et al. · 2023 · Nature Communications
96. Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer
    Adam Kraya, Kara N. Maxwell, Bradley Stephen Wubbenhorst, Brandon M. Wenz, John B. Pluta, Andrew J. Rech, Liza M. Dorfman, Nicole Lunceford, Amanda Barrett, Nandita Mitra et al. · 2019 · Clinical Cancer Research
97. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
    Guangchun Han, Qing Deng, Mario Luiz Marques-Piubelli, Enyu Dai, Minghao Dang, Man Chun John Ma, Xubin Li, Haopeng Yang, Jared M. Henderson, Olga M. Kudryashova et al. · 2022 · Blood Cancer Discovery
98. Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment
    Jiayuan Le, Yating Dian, Deze Zhao, Ziyu Guo, Zehao Luo, Xiang Chen, Furong Zeng, Guangtong Deng · 2025 · Molecular Cancer
99. A Single Cell but Many Different Transcripts: A Journey into the World of Long Non-Coding RNAs
    Enrico Alessio, Raphael Severino Bonadio, Lisa Buson, Francesco Chemello, Stefano Cagnin · 2020 · International Journal of Molecular Sciences
100. A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq
     Angela C. Boroughs, Rebecca C. Larson, Nemanja Despot Marjanovic, Kirk Gosik, Ana P. Castaño, Caroline B. M. Porter, Selena Lorrey, Orr Ashenberg, Livnat Jerby‐Arnon, Matan Hofree et al. · 2020 · Molecular Therapy